Shilpa Medicare Limited has informed the Exchange regarding Board meeting Outcome held on August 13, 2025.
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare's board approved Q1FY26 (quarter ended June 30, 2025) results on August 13, 2025. On a standalone basis, revenue from operations dipped to Rs 9,243 lakhs (vs Rs 9,612 lakhs a year ago), while net profit fell to Rs 2,070 lakhs (vs Rs 2,788 lakhs), pulled down by Rs 518 lakhs in exceptional items related to impairment of advances and investments in foreign subsidiaries. On a consolidated basis, the picture was stronger: revenue rose about 10% to Rs 32,146 lakhs and net profit jumped over 3x to Rs 4,689 lakhs (vs Rs 1,406 lakhs), aided by a Rs 1,137 lakh tax reversal linked to the merger of INM Technologies. The board also declared a 1:1 bonus share issue (record date September 26, 2025), doubling paid-up capital to about Rs 19.56 crore, and approved reclassification of two promoter-group members to public category. Additionally, several director reappointments were cleared, including a new Independent Director. Prior period numbers were restated to reflect the INM Technologies merger.
For shareholders, the bonus issue doubles share count but is typically price-neutral on announcement; the share price may adjust downward to reflect the dilution. The standalone earnings dip and recurring foreign-subsidiary impairments are a concern, but the consolidated profit surge signals strong group-level performance. Tax reversals boosted the quarter's bottom line and won't repeat.